WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
'Bluey' hits the mark with children and adults alike
The EPA is again allowing summer sales of higher ethanol gasoline blend, citing global conflicts
Sweden beats France, Britain relegated after losing to Norway at hockey worlds
John Tortorella says he failed to get Flyers to 'close the deal' in wake of late
The 12 jurors picked in Trump's hush money trial, including a woman who called him 'selfish'
Angela Rayner makes her second visit to a housing project in just four days
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
John Tortorella says he failed to get Flyers to 'close the deal' in wake of late
Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
Nice scores three as lax defending against costs Lorient